Table 1 Participant characteristics by quartile of neutrophil: lymphocyte ratio (NLR) (n = 507)
From: Neutrophil: lymphocyte ratio is positively associated with subclinical diabetic cardiomyopathy
Participant characteristics | Quartiles of NLR (range) | ||||
|---|---|---|---|---|---|
Level 1 (< 1.35) n = 124 | Level 2 (≥1.35 and < 1.77) n = 129 | Level 3 (≥1.77 and < 2.38) n = 127 | Level 4 (≥2.38) n = 127 | P value | |
Sex (male, %) | 80 (64.52%) | 79 (61.24%) | 84 (66.14%) | 70 (55.12%) | 0.894 |
Age (years) | 54.84 ± 8.16 | 54.84 ± 8.16 | 54.84 ± 8.16 | 54.84 ± 8.16 | 0.083 |
BMI (kg/m2) | 23.29 ± 3.43 | 23.64 ± 3.29 | 23.52 ± 3.87 | 23.64 ± 3.64 | 0.935 |
WHR | 1.01 ± 0.91 | 0.93 ± 0.70 | 0.94 ± 0.06 | 0.93 ± 0.06 | 0.430 |
Duration of diabetes (years) | 5.53 ± 4.68 | 6.47 ± 6.24 | 7.24 ± 5.35 | 7.79 ± 5.29 | 0.002* |
FBG (mmol/L) | 9.99 ± 3.03 | 9.58 ± 3.03 | 9.27 ± 2.90 | 9.86 ± 3.26 | 0.246 |
2-h PBG (mmol/L) | 13.80 ± 4.40 | 14.78 ± 5.45 | 13.57 ± 4.94 | 15.12 ± 4.96 | 0.023* |
HbA1c (%) | 9.41 ± 1.75 | 9.62 ± 2.23 | 9.80 ± 2.31 | 10.28 ± 2.51 | 0.026* |
ALT (U/L) | 23.43 ± 14.13 | 24.98 ± 26.39 | 21.97 ± 17.08 | 20.69 ± 13.64 | 0.268 |
AST (U/L) | 23.35 ± 11.87 | 24.09 ± 25.71 | 21.51 ± 12.70 | 20.27 ± 11.75 | 0.250 |
BUN (mmol/L) | 5.21 ± 1.30 | 5.25 ± 1.29 | 5.39 ± 1.46 | 5.32 ± 1.53 | 0.653 |
Cr (mmol/L) | 69.33 ± 14.99 | 67.66 ± 13.07 | 69.93 ± 12.48 | 70.53 ± 13.45 | 0.506 |
BNP (ng/L) | 33.19 ± 22.25 | 33.43 ± 27.71 | 35.52 ± 27.51 | 39.08 ± 25.71 | 0.102 |
CTNI (ng/mL) | 0.0017 ± 0.002 | 0.0025 ± 0.006 | 0.0025 ± 0.004 | 0.0016 ± 0.002 | 0.637 |
CK (U/L) | 74.75 ± 42.10 | 77.00 ± 43.86 | 65.44 ± 20.29 | 72.80 ± 35.44 | 0.540 |
CK-MB (U/L) | 1.47 ± 0.99 | 1.48 ± 0.84 | 1.66 ± 2.33 | 1.41 ± 0.79 | 0.488 |
Myoglobin (ng/mL) | 20.16 ± 11.30 | 19.45 ± 8.68 | 22.10 ± 11.47 | 19.47 ± 7.92 | 0.235 |
TC (mmol/L) | 4.43 ± 1.09 | 4.63 ± 1.36 | 4.74 ± 0.94 | 4.89 ± 2.51 | 0.018* |
TG (mmol/L) | 1.84 ± 1.37 | 1.91 ± 1.37 | 2.38 ± 2.56 | 2.85 ± 1.90 | 0.039* |
HDL (mmol/L) | 1.10 ± 0.35 | 1.09 ± 0.36 | 1.03 ± 0.29 | 1.09 ± 0.32 | 0.190 |
LDL (mmol/L) | 2.55 ± 0.80 | 2.72 ± 0.81 | 2.78 ± 0.62 | 2.82 ± 0.77 | 0.420 |
Hypoglycemic drug use (%) | |||||
Sulfonylurea | 24 (19.35%) | 23 (17.83%) | 24 (18.90%) | 20 (15.75%) | 0.741 |
Metformin | 100 (80.65%) | 105 (81.40%) | 103 (81.10%) | 103 (81.10%) | 0.500 |
α-glucosidase inhibitor | 104 (83.87%) | 110 (85.27%) | 112 (88.19%) | 109 (85.83%) | 0.764 |
GLP-1 | 18 (14.52%) | 17 (13.18%) | 19 (14.96%) | 19 (14.96%) | 0.636 |
DPP4 inhibitor | 11 (8.87%) | 12 (9.30%) | 13 (10.24%) | 13 (10.24%) | 0.473 |
SGLT2 inhibitor | 11 (8.87%) | 13 (10.08%) | 11 (8.66%) | 12 (9.45%) | 0.349 |
Insulin | 88 (70.97%) | 93 (72.09%) | 91 (71.65%) | 90 (70.87%) | 0.523 |